On successful LANI I value it around $30 a share for Biota... talk about massive upside!
The phase II trials will really be a company maker for Biota... much more than anything they have seen to date. Good phase II trials (match effectiveness of Relenza) and I'll guess a stock price of $5+, perhaps $3+ in this crappy market.
It's basically a monopoly drug in a $2bn per annum market with excellent growth prospects. Imagine how many people would buy the product if they just had to take one puff to get rid of the flu. And marketing wouldn't be a problem now the market has been clearly identified by Tamiflu and Relenza.
LANI is biotech gold!
NIH has already backed LANI with USD 5.6 for a nebulised version and USD 8.5 for flunet (a back up to CS - 8958).
Does anyone know if Japan needs FDA approval, or can they go to market with some sort of accelerated process?
up from here, page-15
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)